Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Celiac Disease - Licensing opportunities exist in untapped market

Stakeholder Opinions: Celiac Disease - Licensing opportunities exist in untapped market

Low disease awareness, poor diagnosis rates, combined with a lack of pharmaceutical industry involvement, has kept celiac disease from the limelight. However, this is changing as evidenced by Shire's recent involvement in the pipeline. Datamonitor believes a drug for celiac disease is up to 5 years away and this untapped gastrointestinal indication has the potential to become a lucrative market.

Review of epidemiology, issues with diagnosisboth current techniques and those with future potentialand management of celiac disease, are discussed

Commercial assessment of celiac disease, including market access scenarios and patient number forecast

An overview of unmet needs, the celiac disease pipeline and clinical trial design

Stakeholder opinions based on qualitative interviews with six key opinion leaders in the field of celiac disease

A drug launch in celiac disease is up to 5 years away. Datamonitor estimates that under optimal conditions drug sales could reach $8 billion by 2019 in the seven major markets. Two market access strategies are available to companies, which are dictated by the targeted celiac disease subpopulation and drug price point.

The pipeline is small, and not advanced past Phase II, but candidates show various approaches to potentially treating celiac disease. Small, venture-backed biopharmaceutical companies power R&D, but Shire's recent in-licensing of the lead pipeline candidate AT-1001 (Alba Therapeutics) shows the promise of future Big Pharma involvement.

Low disease awareness among primary care physicians is a major factor behind low diagnosis rates5% in the US to 25% in the EUin celiac disease. Continued efforts to increase awareness, especially once a drug comes to market, will drive celiac disease diagnosis rates up to 50%-60% by 2019, which will expand the overall patient population.

Assess the major diagnostic issues, how these will change and what impact they will have on Datamonitor's celiac disease patient forecast to 2019

Understand the key factors and unmet needs that makes celiac disease an area with significant opportunities

Identify the companies and drug candidates in this advancing gastrointestinal area, and realize the approaches that are shaping R&D in celiac disease

Publication: 39904
Library Code: DMHC2491
Type: Report
Format: PDF & SlidePack
Pages: 150

Table of Contents
Price: $3,800.00 / €2,516.74

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions